Table 1: Non-SN metastasis and pathological factors in patients with one or two metastatic SNs.
| Patients n (%) |
Non-SN metastases | P | |||
|---|---|---|---|---|---|
| Positive 25 (19%) |
Negative 107 (81%) |
||||
| pT | ≦ 0, ≦ 2 cm | 62 (47%) | 8 (13%) | 54 (87%) | 0.06 |
| < 2, ≦5 cm | 64 (48%) | 14 (22%) | 50 (78%) | ||
| < 5 cm | 6 (5%) | 3 (50%) | 3 (50%) | ||
| ER | + | 111 (84%) | 20 (18%) | 91 (82%) | 0.53 |
| - | 21 (16%) | 5 (24%) | 16 (76%) | ||
| PgR | + | 105 (80%) | 21 (20%) | 84 (80%) | 0.60 |
| - | 27 (20%) | 4 (15%) | 23 (85%) | ||
| HER2 | + | 12 (9%) | 5 (42%) | 7 (58%) | 0.035 |
| - | 120 (91%) | 20 (17%) | 100 (83%) | ||
| ly | + | 65 (49%) | 15 (23%) | 50 (77%) | 0.23 |
| - | 67 (51%) | 10 (15%) | 57 (85%) | ||
| v | + | 11 (8%) | 2 (18%) | 9 (82%) | 0.95 |
| - | 121 (92%) | 23 (19%) | 98 (81%) | ||
SN: Sentinel Lymph Node; pT: Pathological Tumor Diameter; ER: Estrogen Receptor; PgR: Progesterone Receptor; HER2: Human Epidermal Growth Factor Receptor-2; ly: Lymphatic Invasion; v: Venous Invasion.